Mineralys Therapeutics (MLYS) Cash from Operations (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Cash from Operations data on file, last reported at 39471000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 13.23% year-over-year to 39471000.0; the trailing twelve-month figure through Mar 2026 stood at 136400000.0 (up 29.2% YoY), and the FY2025 full-year result was 142416000.0, up 14.37% from the prior year.
• Cash from Operations fell to 39471000.0 in Q1 2026, from 37916000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 5469000.0 in Q2 2022 to a low of 66843000.0 in Q4 2024.
• A 5-year average of 26976176.47 and a median of 28800000.0 in 2025 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations tumbled 272.76% in 2023 and jumped 43.28% in 2025, its largest moves.
• Tracing MLYS's Cash from Operations over 5 years: stood at 10186000.0 in 2022, then tumbled by 184.52% to 28981000.0 in 2023, then tumbled by 130.64% to 66843000.0 in 2024, then jumped by 43.28% to 37916000.0 in 2025, then retreated by 4.1% to 39471000.0 in 2026.
• Business Quant data shows MLYS's Cash from Operations at 39471000.0 in Q1 2026, 37916000.0 in Q4 2025, and 28800000.0 in Q3 2025.